While the clinical success of these drugs sets the stage for a new era in anti-obesity medication, there remains considerable controversy as to how GIP regulates metabolism and whether GIP receptor agonism or antagonism is a preferred treatment for obesity and T2D. Here, GIP is linked to obesity disorder.